Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. Its SIRPaFc (TTI-621) program, which is under Phase I clinical trial, is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the fragment crystallizable (Fc) region of a human immunoglobulin (IgG1). It acts as a soluble decoy receptor, preventing CD47 from delivering its inhibitory signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic signals. It also has a medicinal chemistry platform, which permits the creation of new chemical entities from validated drugs and drug candidates with managed pharmacological properties. Its preclinical program is an orally-available bromodomain inhibitor, followed by an epidermal growth factor receptor antagonist with increased uptake in the brain. In addition, a number of compounds are in the discovery phase.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Symbol: TSE:SSS
- CUSIP: N/A
- Web: N/A
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
Frequently Asked Questions for Trillium Therapeutics (TSE:SSS)
What is Trillium Therapeutics' stock symbol?
Trillium Therapeutics trades on the Tornton Stock Exchange (TSX) under the ticker symbol "SSS."
Who are some of Trillium Therapeutics' key competitors?
Some companies that are related to Trillium Therapeutics include Colliers International Group (CIG), Kirkland Lake Gold Ltd (NMI), Osisko Mining Corp (OBM), Royal Bank of Canada (RY), Toronto-Dominion Bank (TD), Bank of Nova Scotia (BNS), Enbridge (ENB), Canadian National Railway Company (CNR), Suncor Energy (SU), Bank of Montreal (BMO), TransCanada (TRP), BCE (BCE), Manulife Financial Corp. (MFC), Canadian Natural Resources Limited (CNQ), Thomson Reuters Corp (TRI), Canadian Imperial Bank of Commerce (CM), Great-West Lifeco (GWO) and Imperial Oil Ltd (IMO).
How do I buy Trillium Therapeutics stock?
Shares of Trillium Therapeutics and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
Consensus Ratings for Trillium Therapeutics (TSE:SSS) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Trillium Therapeutics (TSE:SSS)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Trillium Therapeutics (TSE:SSS)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Trillium Therapeutics (TSE:SSS)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Trillium Therapeutics (TSE:SSS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Trillium Therapeutics (TSE:SSS)Insider Trades by Quarter for Trillium Therapeutics (TSE:SSS)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/2/2017||Michael Bruno John Fr England||Director||Buy||100,000||C$0.15||C$15,000.00|
|4/20/2017||Michael Bruno John Fr England||Director||Buy||11,500||C$0.12||C$1,380.00|
|4/19/2017||Michael Bruno John Fr England||Director||Buy||50,000||C$0.12||C$6,000.00|
|4/13/2017||Donald Laughlin Mckinnon||Director||Buy||20,000||C$0.13||C$2,600.00|
|4/10/2017||Michael Bruno John Fr England||Director||Buy||12,000||C$0.10||C$1,200.00|
|3/27/2017||Michael Bruno John Fr England||Director||Buy||5,000||C$0.19||C$950.00|
|3/22/2017||Gordon Edward Zelko||Director||Buy||20,000||C$0.10||C$2,000.00|
|2/17/2017||Michael Bruno John Fr England||Director||Buy||50,000||C$0.12||C$6,000.00|
|2/7/2017||Gordon Edward Zelko||Director||Buy||50,000||C$0.11||C$5,500.00|
|1/31/2017||Michael Bruno John Fr England||Director||Buy||20,000||C$0.11||C$2,200.00|
Headline Trends for Trillium Therapeutics (TSE:SSS)
Latest Headlines for Trillium Therapeutics (TSE:SSS)
Trillium Therapeutics (SSS) Chart for Sunday, May, 28, 2017